PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 New Preclinical Data Showed OncoPLEX Injected Intratumorally Reduced Tumor Volume and Improved Survival in New Animal Models Recent Successful $16 Million Financing Extends Company’s Cash Runway

Related Keywords

Israel ,Dafna ,Ha Afon ,Dikla Czaczkes Akselbrad ,Brian Ritchie ,Czaczkes Akselbrad ,Company Annual Report On Form ,Twitter ,Polypid Ltd ,Linkedin ,Fund Polypid ,Nasdaq ,More Than ,Abdominal Colorectal Surgical Site ,Interim Analysis ,Conducted Once Approximately ,Complete Their ,Day Follow Up ,Top Line Results Expected ,Second Half ,Intratumorally Reduced Tumor Volume ,Improved Survival ,New Animal ,Financing Extends Company ,Cash Runway Through Late Third Quarter ,Beyond Expected Timing ,Unblinded Interim Analysis ,Potential Additional ,Planned New Drug Application Submission ,Call Scheduled ,Corporate Highlights ,New Drug Application ,Chief Executive ,Call Dial In ,Webcast Information ,Polymer Lipid Encapsulation ,Active Pharmaceutical Ingredients ,Private Securities Litigation Reform Act ,Annual Report ,Polypid ,The Company ,Financial Results ,Business Development ,